title: No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease.
abstract: We recently showed an association between the FCGR3A V/F polymorphism and the biological response [assessed on the basis of a C-reactive protein (CRP) concentration decrease] to infliximab in Crohn's disease. The CRP and FCGR3A genes are located on the same 1q23 locus. The present study aimed: (i) to exclude a linkage disequilibrium (LD) between the two genes and (ii) to study the association between CRP polymorphisms and the response to infliximab, particularly the decrease in CRP after treatment, in Crohn's disease patients. FCGR3A (V/F) polymorphism and three CRP polymorphisms (-717G/A, 1444C/T, CRP 4A/G) were determined in 206 healthy blood donors and 189 Crohn's disease patients who had received infliximab for either refractory luminal or fistulizing Crohn's disease. Clinical response was defined as complete, partial or absent according to the same definition as in controlled trials. The biological response was defined on the basis of CRP decrease. There was no LD between CRP and FCGR3A in healthy donors or Crohn's disease patients. CRP polymorphisms had no impact on CRP decrease after infliximab. The proportions of Crohn's disease having a positive clinical or biological response were not statistically different among the various genotypes of CRP polymorphisms. There was no LD between CRP and FCGR3A polymorphisms. CRP polymorphisms were not associated with the response to infliximab in Crohn's disease.
authors.affiliation: François-Rabelais University, Immuno-Pharmaco-Genetics of Therapeutic Antibodies Research Group (UPRES EA 3853), Tours, France.
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Willot
authors.forename: Severine
authors.initials: S
authors.lastname: Vermeire
authors.forename: Marc
authors.initials: M
authors.lastname: Ohresser
authors.forename: Paul
authors.initials: P
authors.lastname: Rutgeerts
authors.forename: Gilles
authors.initials: G
authors.lastname: Paintaud
authors.forename: Jacques
authors.initials: J
authors.lastname: Belaiche
authors.forename: Martine
authors.initials: M
authors.lastname: De Vos
authors.forename: André
authors.initials: A
authors.lastname: Van Gossum
authors.forename: Denis
authors.initials: D
authors.lastname: Franchimont
authors.forename: Jean-Fréderic
authors.initials: JF
authors.lastname: Colombel
authors.forename: Hervé
authors.initials: H
authors.lastname: Watier
authors.forename: Edouard
authors.initials: E
authors.lastname: Louis
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000235:genetics / Q000378:metabolism*; D003424:Crohn Disease / Q000097:blood* / Q000188:drug therapy / Q000235:genetics; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D002097:C-Reactive Protein; D000069285:Infliximab